Prosper I. Okonkwo, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Nigeria | 51 | 2024 | 770 | 1.770 |
Why?
|
HIV Infections | 50 | 2024 | 17351 | 1.370 |
Why?
|
Anti-HIV Agents | 24 | 2024 | 4527 | 1.170 |
Why?
|
Anti-Retroviral Agents | 11 | 2024 | 1784 | 0.750 |
Why?
|
Medication Adherence | 10 | 2024 | 2176 | 0.750 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 1 | 2021 | 85 | 0.730 |
Why?
|
Viral Load | 20 | 2024 | 3332 | 0.700 |
Why?
|
Drug Resistance, Viral | 6 | 2020 | 862 | 0.550 |
Why?
|
HIV-1 | 11 | 2023 | 6863 | 0.470 |
Why?
|
Rifabutin | 3 | 2024 | 59 | 0.450 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2021 | 934 | 0.430 |
Why?
|
Ritonavir | 3 | 2024 | 329 | 0.390 |
Why?
|
Mycobacterium tuberculosis | 1 | 2021 | 1914 | 0.350 |
Why?
|
Infectious Disease Transmission, Vertical | 4 | 2016 | 1351 | 0.290 |
Why?
|
Lost to Follow-Up | 3 | 2020 | 123 | 0.270 |
Why?
|
Antiretroviral Therapy, Highly Active | 6 | 2019 | 1897 | 0.270 |
Why?
|
Capacity Building | 2 | 2019 | 258 | 0.260 |
Why?
|
Tuberculosis | 4 | 2024 | 2017 | 0.260 |
Why?
|
Universities | 4 | 2020 | 993 | 0.260 |
Why?
|
CD4 Lymphocyte Count | 10 | 2024 | 2571 | 0.260 |
Why?
|
Pregnancy Complications, Infectious | 6 | 2024 | 2151 | 0.250 |
Why?
|
Developing Countries | 5 | 2023 | 2885 | 0.240 |
Why?
|
Antitubercular Agents | 2 | 2024 | 1375 | 0.230 |
Why?
|
Research Personnel | 2 | 2019 | 588 | 0.220 |
Why?
|
Chemoprevention | 2 | 2015 | 326 | 0.200 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2020 | 942 | 0.190 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2023 | 2020 | 0.180 |
Why?
|
Faculty | 2 | 2023 | 384 | 0.180 |
Why?
|
Ambulatory Care Facilities | 4 | 2020 | 935 | 0.170 |
Why?
|
Mental Health Services | 2 | 2022 | 1730 | 0.170 |
Why?
|
Antibiotics, Antitubercular | 1 | 2019 | 99 | 0.160 |
Why?
|
Cost of Illness | 1 | 2008 | 1936 | 0.150 |
Why?
|
Health Services | 1 | 2023 | 752 | 0.150 |
Why?
|
Biomedical Research | 3 | 2020 | 3429 | 0.150 |
Why?
|
Publications | 1 | 2020 | 194 | 0.150 |
Why?
|
Delivery of Health Care | 3 | 2021 | 5336 | 0.140 |
Why?
|
Postpartum Period | 1 | 2024 | 1173 | 0.140 |
Why?
|
Adult | 34 | 2024 | 221177 | 0.140 |
Why?
|
Zidovudine | 2 | 2016 | 624 | 0.140 |
Why?
|
Efficiency | 1 | 2020 | 476 | 0.140 |
Why?
|
National Health Programs | 1 | 2019 | 440 | 0.130 |
Why?
|
Adolescent Health Services | 1 | 2017 | 218 | 0.130 |
Why?
|
Retrospective Studies | 21 | 2024 | 80636 | 0.130 |
Why?
|
Self Care | 2 | 2017 | 796 | 0.130 |
Why?
|
Female | 43 | 2024 | 392644 | 0.120 |
Why?
|
Microbial Sensitivity Tests | 1 | 2021 | 1937 | 0.120 |
Why?
|
Humans | 58 | 2024 | 761504 | 0.120 |
Why?
|
Telemedicine | 2 | 2023 | 3051 | 0.120 |
Why?
|
Nevirapine | 1 | 2015 | 273 | 0.120 |
Why?
|
Male | 38 | 2024 | 360804 | 0.120 |
Why?
|
Program Development | 1 | 2020 | 1297 | 0.120 |
Why?
|
Acetic Acid | 2 | 2023 | 60 | 0.110 |
Why?
|
Health Priorities | 1 | 2016 | 374 | 0.110 |
Why?
|
Viremia | 1 | 2016 | 707 | 0.110 |
Why?
|
Renal Insufficiency | 1 | 2019 | 809 | 0.110 |
Why?
|
Health Resources | 2 | 2020 | 935 | 0.100 |
Why?
|
Pharmacy | 1 | 2014 | 91 | 0.100 |
Why?
|
Appointments and Schedules | 1 | 2016 | 443 | 0.100 |
Why?
|
Young Adult | 14 | 2024 | 59243 | 0.100 |
Why?
|
Hospital Information Systems | 1 | 2014 | 394 | 0.100 |
Why?
|
Health Plan Implementation | 1 | 2014 | 337 | 0.100 |
Why?
|
Genotype | 4 | 2020 | 12990 | 0.090 |
Why?
|
Adolescent | 14 | 2023 | 88319 | 0.090 |
Why?
|
Peptide Hydrolases | 1 | 2013 | 624 | 0.090 |
Why?
|
Mutation, Missense | 1 | 2019 | 2571 | 0.080 |
Why?
|
Treatment Outcome | 13 | 2024 | 64680 | 0.080 |
Why?
|
Medical Records Systems, Computerized | 1 | 2014 | 1192 | 0.080 |
Why?
|
International Cooperation | 1 | 2014 | 1422 | 0.070 |
Why?
|
Patient-Centered Care | 1 | 2017 | 1421 | 0.070 |
Why?
|
Education, Medical | 2 | 2020 | 1725 | 0.070 |
Why?
|
Drug Prescriptions | 1 | 2016 | 1670 | 0.070 |
Why?
|
Continuity of Patient Care | 3 | 2020 | 1069 | 0.070 |
Why?
|
Health Services Accessibility | 3 | 2024 | 5440 | 0.070 |
Why?
|
Quality Improvement | 2 | 2019 | 3801 | 0.070 |
Why?
|
Salvage Therapy | 1 | 2013 | 1264 | 0.070 |
Why?
|
Selection Bias | 1 | 2008 | 359 | 0.070 |
Why?
|
Middle Aged | 12 | 2024 | 220895 | 0.070 |
Why?
|
Cross-Sectional Studies | 7 | 2022 | 26125 | 0.070 |
Why?
|
Africa South of the Sahara | 2 | 2022 | 744 | 0.060 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 3688 | 0.060 |
Why?
|
Drug Monitoring | 1 | 2011 | 962 | 0.060 |
Why?
|
Mentors | 2 | 2023 | 661 | 0.060 |
Why?
|
Point-of-Care Systems | 2 | 2023 | 1213 | 0.060 |
Why?
|
Data Collection | 2 | 2014 | 3322 | 0.060 |
Why?
|
Family Characteristics | 1 | 2008 | 1004 | 0.050 |
Why?
|
Qualitative Research | 3 | 2019 | 3023 | 0.050 |
Why?
|
Morbidity | 1 | 2008 | 1750 | 0.050 |
Why?
|
Isoniazid | 1 | 2024 | 283 | 0.050 |
Why?
|
Health Policy | 3 | 2019 | 2684 | 0.050 |
Why?
|
Infant | 6 | 2024 | 36192 | 0.050 |
Why?
|
Treatment Failure | 2 | 2020 | 2645 | 0.050 |
Why?
|
HIV | 2 | 2023 | 1582 | 0.050 |
Why?
|
HIV Protease Inhibitors | 1 | 2024 | 432 | 0.050 |
Why?
|
Spouse Abuse | 1 | 2002 | 182 | 0.050 |
Why?
|
Cohort Studies | 6 | 2020 | 41487 | 0.050 |
Why?
|
Pregnancy | 6 | 2024 | 29874 | 0.050 |
Why?
|
Mental Disorders | 1 | 2020 | 6845 | 0.040 |
Why?
|
Attitude of Health Personnel | 1 | 2014 | 3889 | 0.040 |
Why?
|
Review Literature as Topic | 1 | 2022 | 348 | 0.040 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2008 | 2199 | 0.040 |
Why?
|
Fees and Charges | 1 | 2020 | 192 | 0.040 |
Why?
|
Community Health Services | 1 | 2024 | 656 | 0.040 |
Why?
|
Hospitals, Teaching | 2 | 2020 | 1156 | 0.040 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 39 | 0.040 |
Why?
|
Cooperative Behavior | 2 | 2018 | 1505 | 0.040 |
Why?
|
Infant, Newborn | 5 | 2019 | 26198 | 0.040 |
Why?
|
Early Detection of Cancer | 2 | 2023 | 3201 | 0.040 |
Why?
|
Socioeconomic Factors | 2 | 2013 | 7827 | 0.040 |
Why?
|
Organizations | 1 | 2019 | 171 | 0.040 |
Why?
|
Patient Dropouts | 1 | 2020 | 412 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2020 | 14605 | 0.040 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2024 | 832 | 0.040 |
Why?
|
Disclosure | 1 | 2023 | 748 | 0.040 |
Why?
|
Mutation | 2 | 2020 | 30052 | 0.040 |
Why?
|
Social Support | 2 | 2017 | 2171 | 0.040 |
Why?
|
Case-Control Studies | 2 | 2020 | 22176 | 0.030 |
Why?
|
Social Stigma | 1 | 2023 | 769 | 0.030 |
Why?
|
RNA, Viral | 2 | 2015 | 2846 | 0.030 |
Why?
|
Caregivers | 1 | 2008 | 2237 | 0.030 |
Why?
|
Unsafe Sex | 1 | 2017 | 238 | 0.030 |
Why?
|
Program Evaluation | 1 | 2024 | 2495 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2019 | 4740 | 0.030 |
Why?
|
Drug Interactions | 1 | 2019 | 1416 | 0.030 |
Why?
|
Child | 5 | 2024 | 80153 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2020 | 12059 | 0.030 |
Why?
|
Patient Acceptance of Health Care | 1 | 2008 | 3205 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2019 | 803 | 0.030 |
Why?
|
Primary Health Care | 2 | 2017 | 4686 | 0.030 |
Why?
|
Self Efficacy | 1 | 2017 | 638 | 0.030 |
Why?
|
Research Support as Topic | 1 | 2018 | 697 | 0.030 |
Why?
|
Logistic Models | 1 | 2008 | 13255 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2017 | 709 | 0.030 |
Why?
|
Peer Group | 1 | 2017 | 692 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2017 | 1440 | 0.020 |
Why?
|
Focus Groups | 1 | 2016 | 1413 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2016 | 2850 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2019 | 2176 | 0.020 |
Why?
|
Self Report | 1 | 2021 | 3724 | 0.020 |
Why?
|
Patient Compliance | 1 | 2020 | 2690 | 0.020 |
Why?
|
Adolescent Behavior | 1 | 2017 | 1190 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2508 | 0.020 |
Why?
|
Patient Preference | 1 | 2016 | 924 | 0.020 |
Why?
|
Health Services Research | 1 | 2016 | 1812 | 0.020 |
Why?
|
Leadership | 1 | 2018 | 1385 | 0.020 |
Why?
|
Hospitalization | 1 | 2008 | 10723 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4853 | 0.020 |
Why?
|
Age Factors | 2 | 2016 | 18395 | 0.020 |
Why?
|
HIV Antibodies | 1 | 2015 | 1303 | 0.020 |
Why?
|
Health Expenditures | 1 | 2020 | 2366 | 0.020 |
Why?
|
Quality Indicators, Health Care | 1 | 2017 | 1792 | 0.020 |
Why?
|
Child, Preschool | 2 | 2024 | 42230 | 0.020 |
Why?
|
Risk Factors | 3 | 2021 | 74206 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2013 | 2707 | 0.020 |
Why?
|
Regression Analysis | 1 | 2016 | 6343 | 0.020 |
Why?
|
Prevalence | 2 | 2020 | 15732 | 0.020 |
Why?
|
Prospective Studies | 2 | 2023 | 54425 | 0.020 |
Why?
|
Patient Care Team | 1 | 2017 | 2521 | 0.020 |
Why?
|
Prenatal Care | 1 | 2013 | 1139 | 0.020 |
Why?
|
Phylogeny | 1 | 2013 | 2811 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6484 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10508 | 0.020 |
Why?
|
Time Factors | 2 | 2017 | 39967 | 0.020 |
Why?
|
Communication | 1 | 2018 | 3873 | 0.010 |
Why?
|
Mental Health | 1 | 2017 | 3250 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2015 | 39106 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 4016 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2020 | 4811 | 0.010 |
Why?
|
Research Design | 1 | 2017 | 6180 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8654 | 0.010 |
Why?
|
Marital Status | 1 | 2002 | 426 | 0.010 |
Why?
|
Marriage | 1 | 2002 | 351 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 17635 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2014 | 4330 | 0.010 |
Why?
|
Rural Health Services | 1 | 2002 | 384 | 0.010 |
Why?
|
Mass Screening | 1 | 2013 | 5428 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14666 | 0.010 |
Why?
|
Quality of Life | 1 | 2017 | 13367 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2011 | 15266 | 0.010 |
Why?
|
Educational Status | 1 | 2002 | 2522 | 0.010 |
Why?
|
Emotions | 1 | 2002 | 2739 | 0.010 |
Why?
|